Several gene mutations including MYD88L265P and CD79B mutations, NOTCH1 mutations, and TP53 mutations are independent risk factors related to poor prognosis in DLBCL patients7,10–15. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.